AU2020316243B2 - Inhibitor compounds - Google Patents

Inhibitor compounds

Info

Publication number
AU2020316243B2
AU2020316243B2 AU2020316243A AU2020316243A AU2020316243B2 AU 2020316243 B2 AU2020316243 B2 AU 2020316243B2 AU 2020316243 A AU2020316243 A AU 2020316243A AU 2020316243 A AU2020316243 A AU 2020316243A AU 2020316243 B2 AU2020316243 B2 AU 2020316243B2
Authority
AU
Australia
Prior art keywords
6alkyl
compound
formula
pharmaceutically acceptable
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020316243A
Other languages
English (en)
Other versions
AU2020316243A1 (en
Inventor
Bernard Luke Flynn
Giang Le
Shuxin YANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincera Therapeutics Pty Ltd
Original Assignee
Cincera Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902614A external-priority patent/AU2019902614A0/en
Application filed by Cincera Therapeutics Pty Ltd filed Critical Cincera Therapeutics Pty Ltd
Publication of AU2020316243A1 publication Critical patent/AU2020316243A1/en
Application granted granted Critical
Publication of AU2020316243B2 publication Critical patent/AU2020316243B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020316243A 2019-07-24 2020-07-24 Inhibitor compounds Active AU2020316243B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902614A AU2019902614A0 (en) 2019-07-24 Inhibitor compounds
AU2019902614 2019-07-24
PCT/AU2020/050763 WO2021012018A1 (en) 2019-07-24 2020-07-24 Inhibitor compounds

Publications (2)

Publication Number Publication Date
AU2020316243A1 AU2020316243A1 (en) 2022-03-03
AU2020316243B2 true AU2020316243B2 (en) 2026-05-21

Family

ID=74192564

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020316243A Active AU2020316243B2 (en) 2019-07-24 2020-07-24 Inhibitor compounds

Country Status (12)

Country Link
US (2) US12448371B2 (cg-RX-API-DMAC7.html)
EP (1) EP4003986A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022542140A (cg-RX-API-DMAC7.html)
KR (1) KR20220041843A (cg-RX-API-DMAC7.html)
CN (1) CN114450281B (cg-RX-API-DMAC7.html)
AU (1) AU2020316243B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022001270A2 (cg-RX-API-DMAC7.html)
CA (1) CA3144506A1 (cg-RX-API-DMAC7.html)
IL (1) IL290087B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022000845A (cg-RX-API-DMAC7.html)
WO (1) WO2021012018A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202201680B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202213792D0 (en) * 2022-09-21 2022-11-02 Benevolentai Bio Ltd New compounds and method
CN117486792A (zh) * 2023-09-26 2024-02-02 北京四环科宝制药股份有限公司 尼可地尔中间体及其制备方法
US11912675B1 (en) 2023-10-11 2024-02-27 King Faisal University N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound
US11919872B1 (en) 2023-10-11 2024-03-05 King Faisal University N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound
US11891366B1 (en) 2023-10-12 2024-02-06 King Faisal University 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound
US11999706B1 (en) 2023-10-13 2024-06-04 King Faisal University 4-chloro-N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008142073A1 (en) * 2007-05-22 2008-11-27 Novartis Ag Benzamides useful as s1p receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2923661A (en) 1957-03-22 1960-02-02 Irwin Neisler And Co N-[2-(1-phenyl-propyl)]-2, 2, 2-trichloroethylidenimine
US5684018A (en) 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
FI982268L (fi) 1998-10-20 2000-04-21 Tomi Jaervinen Ei-steroidaalisten anti-inflammatoristen karboksyylihappojen uudet pro drugit, niiden valmistus ja käyttö
WO2012164103A2 (en) * 2011-06-03 2012-12-06 Universität Zürich Blockers of the nogo-a s1pr pathway for the treatment of diseases characterized by neuronal damage and lack of subsequent repair
WO2015155738A2 (en) * 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US9828351B2 (en) * 2014-06-26 2017-11-28 Monash University Enzyme interacting agents
WO2018112077A1 (en) 2016-12-13 2018-06-21 Centaurus Therapeutics Inhibitors of dihydroceramide desaturase for treating disease
CN108079303A (zh) * 2017-12-14 2018-05-29 广东药科大学 鞘氨醇激酶抑制剂在制备治疗肝纤维化药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008142073A1 (en) * 2007-05-22 2008-11-27 Novartis Ag Benzamides useful as s1p receptor modulators

Also Published As

Publication number Publication date
CN114450281A (zh) 2022-05-06
US20220274970A1 (en) 2022-09-01
BR112022001270A2 (pt) 2022-06-14
US12448371B2 (en) 2025-10-21
ZA202201680B (en) 2026-05-27
MX2022000845A (es) 2022-04-20
IL290087B1 (en) 2026-01-01
AU2020316243A1 (en) 2022-03-03
CA3144506A1 (en) 2021-01-28
EP4003986A1 (en) 2022-06-01
CN114450281B (zh) 2024-08-16
KR20220041843A (ko) 2022-04-01
WO2021012018A1 (en) 2021-01-28
EP4003986A4 (en) 2023-03-01
US20260001870A1 (en) 2026-01-01
JP2025134819A (ja) 2025-09-17
IL290087A (en) 2022-03-01
IL290087B2 (en) 2026-05-01
JP2022542140A (ja) 2022-09-29

Similar Documents

Publication Publication Date Title
US12448371B2 (en) Inhibitor compounds
US12071433B2 (en) HMOX1 inducers
CN110156770B (zh) 作为tam族激酶抑制剂的氨基吡啶衍生物
US8063084B2 (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
JP5042314B2 (ja) 慢性骨髄増殖疾患および他の増殖性疾患の治療のために有用なキナーゼ阻害剤
US7816558B2 (en) Triarylcarboxylic acid derivative
US20070078121A1 (en) Enzyme modulators and treatments
BG108244A (bg) Производни на пиразол използвани за лечение на hiv
AU2007256708A1 (en) Organic compounds
MXPA02004647A (es) Compuestos heterociclicos de 5 miembros que contienen nitrogeno.
JP2006504711A (ja) インダゾールカルボキサミド誘導体、それらの製造法ならびにcdk1、cdk2およびcdk4阻害剤としての用途
CA2647338A1 (en) Integrase inhibitors-3
KR102214222B1 (ko) 신규 pde4 저해제
AU2012245082A1 (en) Aromatic amides and uses thereof
CA2656159C (en) Pyridylisoxazole derivatives
JPWO2003035638A1 (ja) 4−イミダゾリン−2−オン化合物
CA2591912C (en) Pyrimidinylisoxazole derivatives
CN118696034A (zh) 作为rad51抑制剂的新型双环化合物
AU2020264679B2 (en) Selective ligands of human constitutive androstane receptor
CZ34975U1 (cs) Ligandy lidského konstitutivního adrostanového receptoru
US20240217969A1 (en) Substituted pyrrole carboxamides, process for their preparation and their use as kinase inhibitors
HK40066338B (en) Hmox1 inducers
HK40066338A (en) Hmox1 inducers